Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D03BKV
|
|||
| Former ID |
DIB014214
|
|||
| Drug Name |
KML-001
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C76-C80; ICD-9: 140-229] | Phase 1 | [1] | |
| Company |
Komipharm International Co Ltd
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C16H15ClN2O4
|
|||
| Canonical SMILES |
CC(C1=CC=C(C=C1)Cl)NC(=O)COC2=CC=C(C=C2)[N+](=O)[O-]
|
|||
| InChI |
1S/C16H15ClN2O4/c1-11(12-2-4-13(17)5-3-12)18-16(20)10-23-15-8-6-14(7-9-15)19(21)22/h2-9,11H,10H2,1H3,(H,18,20)
|
|||
| InChIKey |
FIOKOSHFWPOUGX-UHFFFAOYSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Telomerase reverse transcriptase (TERT) | Target Info | Inhibitor | [2] |
| NetPath Pathway | IL2 Signaling Pathway | |||
| Pathway Interaction Database | Validated targets of C-MYC transcriptional activation | |||
| Regulation of Telomerase | ||||
| IL2 signaling events mediated by PI3K | ||||
| Regulation of nuclear beta catenin signaling and target gene transcription | ||||
| HIF-1-alpha transcription factor network | ||||
| Reactome | Formation of the beta-catenin:TCF transactivating complex | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01110226) Trial Of Cisplatin And KML-001 in Platinum Responsive Malignancies. U.S. National Institutes of Health. | |||
| REF 2 | National Cancer Institute Drug Dictionary (drug id 672554). | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.